ArticleFrontiers of medicine2023

BGB-A445, a novel non-ligand-blocking agonistic anti-OX40 antibody, exhibits superior immune activation and antitumor effects in preclinical models.

Beibei Jiang et al.PubMed ↗Publisher ↗

No numbers read from the abstract.